Metastasis shows: the risk of suicide increases significantly with antidepressants
According to metastases, antidepressants increase the suicidal rate of subjects in clinical trials for factor 2.5 compared with placebo. This is, according to scientists, often due to sudden changes in dosage and excessive prescribing.
Salzburg (Austria). Zürich (Switzerland). Scientists from the University of Applied Sciences in Zürich (ZHAW) and the Department of Psychiatry, Psychotherapy and Psychosomatics in Salzburg have published a meta-study in the journal Psychotherapy and Psychosomatics, which deals with the consequences of antidepressant treatment. According to research findings, drugs may cause counteracting effects at the beginning of treatment and instead of helping to increase suicidal risk for patients.
Data from antidepressant trials from 1987 to 2013, which had to be submitted to the US Food and Drug Administration (FDA) prior to the approval of new drugs, were included in the metastatic study. Evaluation shows that in all antidepressant studies, the suicide rate of the control group receiving placebo alone was 0.3 percent, while in the group receiving effective antidepressant suicide rate was 0.8 percent. Deviation can be determined irrespective of the drug in all assays.
Suicidal risk of antidepressants 2.5 times higher
The meta-study concludes that the risk of suicide increases by 2.5 times due to the use of antidepressants. According to the authors of the study, distribution of patients to placebo and antidepressant groups was quite random. Because of the large number of people, there are other factors that could affect the suicide rate, and thus disrupt the results. Since these were double blind studies, the doctors did not know which person had received the medicine before the end of the study.
According to a statistical analysis, subjects in clinical trials experienced suicide in each of 202 patients who did not have placebo therapy. The results therefore encourage discussion of the effectiveness of psychotropic drugs, whose use for years is controversial for doctors and scientists.